24-Hour Crisis Hotline: (877)SAFEGBC or (877)723-3422 Mental Health & Substance Abuse Issues

6502 Nursery Drive, Suite 100
Victoria, TX 77904
(361)575-0611
(800)421-8825
Fax: (361)578-5500

Medical Disorders
Resources
Basic InformationLookupsLatest News
Health Tip: Controllable Stroke Risk FactorsDon't Let Fear of Cancer Keep You From Doctor VisitsScientists Discover New Way Fat Harms Your ArteriesOpioid Prescriptions for Eye Surgery Patients SurgeCases of Vaping-Linked Lung Illness Rise to 530 Across 38 States: CDCHealth Tip: Gaining WeightCan You Still Be Healthy If You're Overweight?Intense Gaming Can Trigger Irregular Heartbeat, Fainting in Some PlayersAll-in-One Pill Helps Protect HeartTiny Genetic Tweak May Stop Ebola Virus in Its TracksOpioid Epidemic Tied to Doubling of Dangerous Heart InfectionsWill Feeding Your Pets Raw Food Make You Sick?AHA News: Vitamin D Is Good for the Bones, But What About the Heart?Health Tip: Understanding Color BlindnessCould Profit Be a Factor in Kidney Transplant Decisions?Could Daily Low-Dose Aspirin Still Help Some People?Health Tip: Relieving Itchy SkinExperts' Guide to Trampoline SafetyHow to Keep Your Feet on a Sound, Pain-Free FootingMost Cyclists Suffering Head Injuries Not Wearing Helmets: StudyLinks Between Smog, 2nd Pregnancies and Preterm BirthHeartburn Drug Zantac May Contain Small Amounts of Known Carcinogen, FDA SaysCDC Revises Number of Vaping-Linked Lung Illnesses to 380 in 36 StatesKidney Transplants Safe When Donors Had Hepatitis CLung Cancer Screening Can Detect Other Smoking IllsIs Your State One of the 'Most Obese' in America?How to Keep Your Bones Strong and Prevent FracturesHeart Attack Can Be More Lethal If Symptoms Are More GradualHealth Tip: Understanding MononucleosisNew Strain of Strep Causing Cases of Scarlet FeverHow to Fight Hidden Causes of InflammationFDA Approves First Treatment for ILD With Systemic Sclerosis, SclerodermaOccasional Naps Do a Heart Good, Swiss Study FindsA 'Supercool' Breakthrough for Patients Awaiting Liver TransplantTreatment for Very-Preterm Infants May Lead to Antibiotic ResistanceWhy Weight Gain Often Comes With AgeNew Prosthetic Leg Can Feel Touch, Reduce 'Phantom Limb' PainThe Alexander Technique: What Could It Do for You?Drink Coffee, Avoid Gallstones?Dark Skin No Protection Against Sun's Harmful RaysSome People Vaccinated Against Mumps May Not Be Protected: StudyDiabetes Control Has Stalled Across U.S.Vaping-Linked Lung Illnesses Double, Vitamin E Acetate Leading Suspect'First Responders' on 9/11 Face Lingering Heart Woes, Study FindsHealth Officials Close in on Culprit in Vaping Lung Injury CasesGoing Vegetarian Good for Your Heart, But May Up Stroke RiskEven Small Improvements in Cholesterol, Blood Pressure Help Prevent Heart AttackHealth Tip: Signs of GallstonesHigh Post-Hospital Death Rate Trails Ebola SurvivorsClues to Why Epileptic Seizures Can Halt Breathing
Questions and AnswersLinks
Related Topics

Diabetes

New Antibiotic Approved for Community-Acquired Bacterial Pneumonia


HealthDay News
Updated: Aug 19th 2019

new article illustration

MONDAY, Aug. 19, 2019 (HealthDay News) -- Xenleta (lefamulin) has been approved to treat adults with community-acquired bacterial pneumonia, the U.S. Food and Drug Administration announced today.

Dosing of Xenleta is either an oral administration of 600 mg every 12 hours or an intravenous administration of 150 mg every 12 hours for five to seven days. Patients can be started on either intravenous or oral therapy or can transition from intravenous to oral therapy to accelerate hospital discharge.

Approval was based on data from two clinical trials of 1,289 patients with community-acquired bacterial pneumonia comparing Xenleta taken orally or intravenously to treatment with moxifloxacin with or without linezolid. Clinical success rates of patients treated with Xenleta were similar to those of patients treated with moxifloxacin with or without linezolid.

The most commonly reported adverse reactions with Xenleta include diarrhea, nausea, injection site reactions, elevated liver enzymes, and vomiting. The FDA notes that Xenleta can cause a prolonged QT interval, so patients with arrythmias, those taking antiarrhythmic agents, and patients receiving other drugs that prolong the QT interval should avoid Xenleta. Patients with known hypersensitivity to lefamulin, other members of the pleuromutilin antibiotic class, or any components of Xenleta are also contraindicated. Health care providers should advise pregnant women and those who could become pregnant of the risk for fetal harm with Xenleta as shown in animal studies. Women who could become pregnant should use effective contraception during and two days after taking Xenleta.

Approval of Xenleta was granted to Nabriva Therapeutics. The drug is expected to be available in mid-September with a wholesale acquisition price of $205 per IV patient treatment day and $275 per oral patient treatment day.

More Information